Sign up to save your podcasts
Or
Share S01 Ep. 10 Collaborative Oncology: Surgeon’s Perspective and Role in Locoregional Therapy with Dr. Robert Martin
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S01 Ep. 10 Collaborative Oncology: Surgeon’s Perspective and Role in Locoregional Therapy with Dr. Robert Martin
Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.
---
This podcast is supported by:
RADPAD® Radiation Protection
https://www.radpad.com/
---
SYNPOSIS
Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care.
---
TIMESTAMPS
00:00 - Introduction
02:31 - Dr. Martin’s Background and Career Path
06:18 - Evolution of Liver Directed Therapies
10:12 - Collaboration Between Specialties
18:34 - Clinical Trials and Emerging Therapies
36:08 - Advice for Young Professionals
39:15 - Conclusion
---
RESOURCES
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC:
https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1):
https://clinicaltrials.gov/study/NCT05688280
Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3:
https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/
View all episodes
By BackTable Inc.Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.
---
This podcast is supported by:
RADPAD® Radiation Protection
https://www.radpad.com/
---
SYNPOSIS
Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care.
---
TIMESTAMPS
00:00 - Introduction
02:31 - Dr. Martin’s Background and Career Path
06:18 - Evolution of Liver Directed Therapies
10:12 - Collaboration Between Specialties
18:34 - Clinical Trials and Emerging Therapies
36:08 - Advice for Young Professionals
39:15 - Conclusion
---
RESOURCES
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC:
https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1):
https://clinicaltrials.gov/study/NCT05688280
Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3:
https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/